DELUGE BIOTECHNOLOGIES INC

Jupiter, FL · Biotech · Private

DNA-encoded libraries of cell-permeable non-peptidic macrocycles for screening against protein-protein interaction targets

Claim this profile

Follows are private to you and power your alerts

Updated · delugebiotechnologies.com

Sector
Biotech
Headquarters
Jupiter, FL
Total capital
$3.9M
Federal grants
$3.9M
8 awards · 2018–2023
Rank in peer group#192 of 326
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $3.9M$225K$225K$1.5M$734K$734K$275K
201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $3.9M$1.5M$734K$734K$275K

Latest events

  • Federal grantHealth and Human S · Phase I · High-Throughput Screening for the Discovery of Protein-Binding Fragments$275K
  • Federal grantHealth and Human S · Phase II · Synthesis and screening of DNA-encoded Libraries of Non-Peptidic Macrocycles$734K
  • Federal grantHealth and Human S · Phase I · Asymmetric synthesis of DNA-encoded libraries of natural product-like compounds.$223K
  • Federal grantHealth and Human S · Phase II · Synthesis and screening of DNA-encoded Libraries of Non-Peptidic Macrocycles$734K
  • Federal grantHealth and Human S · Phase II · Synthesis and screening of DNA-encoded Libraries of Non-Peptidic Macrocycles$1.5M
  • Federal grantHealth and Human S · Phase I · DNA-decoded Libraries of Reversible, Covalent Protein Ligands$225K
  • Federal grantHealth and Human S · Phase I · I-Corps Supplement to parent grant DNA Encoded Macrocycles Libraries As A Source of Protein-Protein Interaction Inhibitors$55K
Show 1 earlier federal award
  • Federal grantHealth and Human S · Phase I · DNA Encoded Macrocycles Libraries As A Source of Protein-Protein Interaction Inhibitors$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .